Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
techcrunch.com Sep 23, 2026

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

AI-summarised brief · reviewed before publication

Enveda, a biotech startup that applies artificial intelligence to identify drugs from natural sources, secured $311 million in a Series E round, elevating its valuation to $2 billion. The funding, led by Catalio Capital Management with participation from Iconiq and other investors, doubles the company’s valuation from a year earlier. Founded in 2019 by Viswa Colluru, Enveda focuses on accelerating discovery of plant- and microbe-derived therapeutics. It currently advances several candidates into human trials, including treatments for severe skin conditions and post‑GLP‑1 weight‑loss maintenance.

💡 Why It Matters

  • · The infusion underscores growing investor confidence in AI‑driven natural product discovery, positioning Enveda as a key player in expanding the pipeline of biologically sourced therapeutics.